Finally, using mouse PDA models, we showed that shRNA knock-downof ANXA2, a mutation at tyrosine 23, or anti-ANXA2 antibodies,inhibit PDA metastases and prolong mouse survival. The gene discussed is ANXA2; the disease is Patent ductus arteriosus.